[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636609":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":44,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Guangzhou Medical University","OTHER",[8,11,13],{"label":9,"type":10,"description":10,"interventionNames":10},"pneumonia",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Severe pneumonia",{"label":14,"type":10,"description":10,"interventionNames":10},"Non-infection control group",[16],{"name":17,"affiliation":18,"role":19},"Zifeng Yang, Doctor","The First Affiliated Hospital of Guangzhou Medical University","STUDY_CHAIR",[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Liang Peng, Doctor","CONTACT","86-020-85959142","pl_206@126.com",[27],{"facility":28,"status":10,"city":29,"state":30,"zip":10,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Fifth Affiliated Hospital of Guangzhou Medical University","Guangzhou","Guangdong","China",{"type":33,"coordinates":34},"Point",[35,36],113.25,23.11667,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Zhonghao Fang","Doctor",[45],{"name":28,"class":6},"100636609",false,"NCT07567911","A Prospective Observational Cohort Study Protocol for Disease Severity Stratification and Prognosis Assessment in Patients With Pneumonia","1. Inclusion and Exclusion Criteria for Pneumonia Patients 1.1 Inclusion Criteria 1) Age ≥ 18 years old; 2) Meeting the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging); 3) Time from onset to admission ≤ 72 hours; 4) Signed written informed consent. 1.1.1 Inclusion Criteria for Severe Pneumonia Patients A diagnosis of \"severe pneumonia\" can be made if one of the main criteria or ≥ 3 of the secondary criteria are met.\n\n   Main Criteria:\n\n   ① Requires mechanical ventilation with tracheal intubation\n\n   ② Requires vasopressor drugs after aggressive fluid resuscitation for septic shock\n\n   Secondary Criteria:\n   * Respiratory rate ≥ 30 breaths\u002Fmin\n\n     * PaO₂\u002FFiO₂ ≤ 250 mm Hg\n\n       * Multiple lobe infiltrates\n\n         * Confusion and\u002For disorientation\n\n           ⑤ Blood urea nitrogen ≥ 20 mg\u002FdL\n\n           ⑥ Leukopenia (WBC \\\u003C 4×10⁹\u002FL)\n\n           ⑦ Thrombocytopenia (PLT \\\u003C 100×10⁹\u002FL)\n\n           ⑧ Decreased body temperature (central body temperature \\\u003C 36 ℃)\n\n           ⑨ Hypotension requiring fluid resuscitation 1.2 Exclusion Criteria\n           1. End-stage diseases (such as expected survival \\\u003C 48 hours);\n           2. Long-term immunosuppressive therapy (prednisone \\> 20mg\u002Fd for more than 3 weeks, or neutropenia after chemotherapy);\n           3. Pregnant or lactating women. 2. Inclusion and Exclusion Criteria for Patients with Suspected Infection but Negative Pathogen Testing 2.1 Inclusion Criteria\n\n           \u003C!-- -->\n\n           1. Age ≥ 18 years old;\n           2. Having infection-related symptoms or signs (such as fever, cough, sputum production, elevated white blood cells, etc.), clinically suspected of pneumonia;\n           3. All pathogen tests are negative within 3 days after admission;\n           4. Time from onset to admission ≤ 72 hours;\n           5. Signed written informed consent. 2.2 Exclusion Criteria\n\n           \u003C!-- -->\n\n           1. End-stage diseases (such as expected survival \\\u003C 48 hours);\n           2. Long-term immunosuppressive therapy;\n           3. Pregnant or lactating women;","ALL","18 Years",{"count":54,"type":55},2700,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter observational cohort study involving approximately 2,700 patients, designed to delineate the natural history of pneumonia by tracking the complete clinical course and dynamic multi-omics evolution from the acute phase to recovery; the study aims to quantify severe conversion rates and mortality by comparing baseline characteristics, pathogen distribution, and immune response trajectories between severe and non-severe groups, ultimately revealing the underlying molecular mechanisms of disease progression and optimizing clinical risk stratification strategies.",[59,60],"Severe Pneumonia","Pneumonia",[9,62],"severe pneumonia","NOT_YET_RECRUITING","2026-04-28",{"date":66,"type":67},"2026-05-05","ACTUAL",{"date":69,"type":55},"2026-05-01",{"date":71,"type":55},"2028-05-28",{"name":42,"class":6},1]